Return on Equity (ROE): 10.58%
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 10.58% is 56% below its 5-year average of 23.86%, near the low end of its 5-year range (10.38%–41.75%).
As of Sunday, June 28, 2026. 59.41% below its 12-month average of 26.07%.
EW Return on Equity (ROE) Chart
Annual fiscal-year return on equity; no daily interpolation.
EW Average Return on Equity (ROE) Chart
EW Current vs Average Return on Equity (ROE) Chart
EW Return on Equity (ROE) Metrics
RETURN ON EQUITY (ROE)
10.58%
RETURN ON EQUITY (ROE) AVG TTM
26.07%
RETURN ON EQUITY (ROE) AVG 3Y
24.86%
RETURN ON EQUITY (ROE) AVG 5Y
23.86%
RETURN ON EQUITY (ROE) AVG 10Y
23.06%
RETURN ON EQUITY (ROE) AVG 15Y
20.80%
RETURN ON EQUITY (ROE) AVG 20Y
19.38%
CURRENT VS TTM AVG
-59.41%
CURRENT VS 3Y AVG
-57.44%
CURRENT VS 5Y AVG
-55.67%
CURRENT VS 10Y AVG
-54.13%
CURRENT VS 15Y AVG
-49.14%
CURRENT VS 20Y AVG
-45.40%
EW Competitors' Return on Equity (ROE)
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Edwards Lifesciences Corporation (EW) | $52.27B | 10.58% | 26.07% | 24.86% | 23.86% |
| Cencora, Inc. (COR)vs › | $55.67B | 75.01% | 168.34% | -32.99% | 148.52% |
| Cardinal Health, Inc. (CAH)vs › | $55.72B | -56.13% | -41.33% | 9.62% | -22.30% |
| Becton, Dickinson and Company (BDX)vs › | $56.49B | 4.72% | 6.60% | 6.50% | 6.42% |
| Humana Inc. (HUM)vs › | $46.08B | 6.08% | 7.05% | 11.93% | 15.09% |
| IDEXX Laboratories, Inc. (IDXX)vs › | $43.50B | 70.38% | 60.82% | 72.53% | 81.69% |
| Regeneron Pharmaceuticals, Inc. (REGN)vs › | $65.20B | 14.08% | 14.72% | 15.95% | 23.11% |
| Boston Scientific Corporation (BSX)vs › | $65.74B | 13.74% | 10.21% | 8.16% | 6.40% |
| Agilent Technologies, Inc. (A)vs › | $38.41B | 19.85% | 20.59% | 21.51% | 20.54% |
| Medline Inc. (MDLN)vs › | $32.87B | 8.55% | 9.02% | 4.86% | 4.86% |
Return Analysis
ROE
10.6%
ROA
8.2%
Return on Equity (ROE) Formula & Definition
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Return on Equity (ROE) FAQ
- What is the return on equity (ROE) for Edwards Lifesciences Corporation (EW)?
- The return on equity (ROE) for EW stock is 10.58%.
- Is Edwards Lifesciences Corporation's return on equity (ROE) high or low?
- The return on equity (ROE) of 10.58% is 56% below its 5-year average of 23.86%, near the low end of its 5-year range (10.38%–41.75%).
- What is the TTM average return on equity (ROE) for Edwards Lifesciences Corporation (EW)?
- The TTM average return on equity (ROE) for EW stock is 26.07%.
- What is the 3Y average return on equity (ROE) for Edwards Lifesciences Corporation (EW)?
- The 3Y average return on equity (ROE) for EW stock is 24.86%.
- What is the 5Y average return on equity (ROE) for Edwards Lifesciences Corporation (EW)?
- The 5Y average return on equity (ROE) for EW stock is 23.86%.
- What is the 10Y average return on equity (ROE) for Edwards Lifesciences Corporation (EW)?
- The 10Y average return on equity (ROE) for EW stock is 23.06%.
- What is the 15Y average return on equity (ROE) for Edwards Lifesciences Corporation (EW)?
- The 15Y average return on equity (ROE) for EW stock is 20.80%.
- What is the 20Y average return on equity (ROE) for Edwards Lifesciences Corporation (EW)?
- The 20Y average return on equity (ROE) for EW stock is 19.38%.
EW Return on Equity (ROE) History
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | 10.38% |
| 2024-12-31 | 41.75% |
| 2023-12-31 | 21.09% |
| 2022-12-31 | 26.21% |
| 2021-12-31 | 25.76% |
| 2020-12-31 | 18.00% |
| 2019-12-31 | 25.24% |
| 2018-12-31 | 23.00% |
| 2017-12-31 | 20.77% |
| 2016-12-31 | 21.74% |
| 2015-12-31 | 19.77% |
| 2014-12-31 | 37.01% |
| 2013-12-31 | 25.12% |
| 2012-12-31 | 19.82% |
| 2011-12-31 | 17.69% |
| 2010-12-31 | 16.66% |
| 2009-12-31 | 19.79% |
| 2008-12-31 | 14.67% |
| 2007-12-31 | 13.53% |
| 2006-12-31 | 17.41% |
| 2005-12-31 | 11.49% |
| 2004-12-31 | 0.27% |
| 2003-12-31 | 12.44% |
| 2002-12-31 | 10.33% |
| 2001-12-31 | -2.61% |
| 2000-12-31 | -61.82% |
| 1999-12-31 | 6.70% |
Related Metrics
About Edwards Lifesciences Corporation
Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Bernard J. Zovighian